Telavancin for the Treatment of Nosocomial Pneumonia Caused by Methicillin-resistant Staphylococcus Aureus (MRSA)

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2012 May 2

PMID 22547931

Citations 5

Authors

Candace Y Hooper

Winter J Smith

Affiliations

Soon will be listed here.

Abstract

Telavancin is a bactericidal lipoglycopeptide antibiotic that is structurally related to vancomycin. It demonstrates in vitro activity against a variety of Gram-positive pathogens including, but not limited to, methicillin-resistant Staphylococcus aureus (MRSA). Telavancin is currently FDA-approved for the treatment of complicated skin and skin-structure infections. Recently, two randomized clinical trials demonstrated the efficacy and safety of telavancin compared to vancomycin for the treatment of nosocomial pneumonia. Overall, telavancin has a favorable safety profile. However, mild gastrointestinal disturbances and reversible increases in serum creatinine were observed in clinical studies. Additional clinical studies are needed to evaluate telavancin's efficacy and safety in comparison to other antistaphylococcal agents for the treatment of infections such as bacteremia and endocarditis.

Citing Articles

Management of methicillin-resistant mediated ventilator-associated pneumonia.

Dahal M, Schwan W Curr Trends Microbiol. 2019; 12:95-107.

PMID: 31341354 PMC: 6656405.

Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?.

Chuan J, Zhang Y, He X, Zhu Y, Zhong L, Yu D Front Pharmacol. 2016; 7:330.

PMID: 27721793 PMC: 5033967. DOI: 10.3389/fphar.2016.00330.

Metataxonomic and Metagenomic Approaches vs. Culture-Based Techniques for Clinical Pathology.

Hilton S, Castro-Nallar E, Perez-Losada M, Toma I, McCaffrey T, Hoffman E Front Microbiol. 2016; 7:484.

PMID: 27092134 PMC: 4823605. DOI: 10.3389/fmicb.2016.00484.

Development of novel antibacterial drugs to combat multiple resistant organisms.

Bassetti M, Righi E Langenbecks Arch Surg. 2015; 400(2):153-65.

PMID: 25667169 DOI: 10.1007/s00423-015-1280-4.

New antibiotics for bad bugs: where are we?.

Bassetti M, Merelli M, Temperoni C, Astilean A Ann Clin Microbiol Antimicrob. 2013; 12:22.

PMID: 23984642 PMC: 3846448. DOI: 10.1186/1476-0711-12-22.

References

Sakoulas G, Moise-Broder P, Schentag J, Forrest A, Moellering Jr R, Eliopoulos G . Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004; 42(6):2398-402. PMC: 427878. DOI: 10.1128/JCM.42.6.2398-2402.2004. View

Leadbetter M, Adams S, Bazzini B, Fatheree P, Karr D, Krause K . Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo). 2004; 57(5):326-36. DOI: 10.7164/antibiotics.57.326. View

Liu C, Bayer A, Cosgrove S, Daum R, Fridkin S, Gorwitz R . Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011; 52(3):285-92. DOI: 10.1093/cid/cir034. View

Cruciani M, Gatti G, Lazzarini L, Furlan G, Broccali G, Malena M . Penetration of vancomycin into human lung tissue. J Antimicrob Chemother. 1996; 38(5):865-9. DOI: 10.1093/jac/38.5.865. View

Wong S, Sorgel F, Kinzig M, Goldberg M, Kitt M, Barriere S . Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. J Clin Pharmacol. 2009; 49(7):816-23. DOI: 10.1177/0091270009337133. View

. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171(4):388-416. DOI: 10.1164/rccm.200405-644ST. View

Wong S, Goldberg M, Ballow C, Kitt M, Barriere S . Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy. 2010; 30(2):136-43. DOI: 10.1592/phco.30.2.136. View

Ambrose P, Bhavnani S, Ellis-Grosse E, Drusano G . Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!. Clin Infect Dis. 2010; 51 Suppl 1:S103-10. DOI: 10.1086/653057. View

Krause K, Renelli M, Difuntorum S, Wu T, Debabov D, Benton B . In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother. 2008; 52(7):2647-52. PMC: 2443888. DOI: 10.1128/AAC.01398-07. View

10.

MacGowan A, Noel A, Tomaselli S, Elliott H, Bowker K . Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother. 2010; 55(2):867-73. PMC: 3028790. DOI: 10.1128/AAC.00933-10. View

11.

Chastre J, Fagon J . Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002; 165(7):867-903. DOI: 10.1164/ajrccm.165.7.2105078. View

12.

Wunderink R, Rello J, Cammarata S, Croos-Dabrera R, Kollef M . Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003; 124(5):1789-97. View

13.

Goldberg M, Wong S, Shaw J, Kitt M, Barriere S . Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy. 2010; 30(8):806-11. DOI: 10.1592/phco.30.8.806. View

14.

Wong S, Barriere S, Kitt M, Goldberg M . Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother. 2008; 62(4):780-3. DOI: 10.1093/jac/dkn273. View

15.

Tablan O, Anderson L, Besser R, Bridges C, Hajjeh R . Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep. 2004; 53(RR-3):1-36. View

16.

Slatter J, Adams L, Bush E, Chiba K, Daley-Yates P, Feenstra K . Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica. 2002; 32(10):907-24. DOI: 10.1080/00498250210158249. View

17.

Rybak M . The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2005; 42 Suppl 1:S35-9. DOI: 10.1086/491712. View

18.

Stevens D . The role of vancomycin in the treatment paradigm. Clin Infect Dis. 2005; 42 Suppl 1:S51-7. DOI: 10.1086/491714. View

19.

Kollef M . The prevention of ventilator-associated pneumonia. N Engl J Med. 1999; 340(8):627-34. DOI: 10.1056/NEJM199902253400807. View

20.

Hegde S, Reyes N, Wiens T, Vanasse N, Skinner R, McCullough J . Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother. 2004; 48(8):3043-50. PMC: 478526. DOI: 10.1128/AAC.48.8.3043-3050.2004. View